Interv Akut Kardiol. 2005;4(2):90-92

LABORATORY ASSESSMENT OF HAEMOSTASIS IN CARDIOLOGICAL INTERVENTIONS

prof. MUDr. Jaroslav Malý CSc1, Miroslav Pecka1, MUDr. Petr Dulíček Ph.D2, MUDr. Martin Blažek2
1 I. interní klinika Fakultní nemocnice v Hradci Králové
2 II. interní klinika, odd. klinické hematologie FN Hradec Králové

Currently a number of clinical conditions are known, in which it is necessary to maintain coagulation decreased. On one hand, these medications can be life-saving, on the other hand, their inappropriate dosage can be life-threatening. Therefore it is essential to adhere to strict indications, intervals monitoring and the recommended therapeutic range when administering these medications. Laboratory monitoring of parameters of haemostasis during antithrombotic treatment or prevention in cardiology is a fundamental prerequisite for successful cardiologic intervention.

Keywords: Key words: antithrombotic treatment, monitoring of antithrombotic treatment.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malý J, Pecka M, Dulíček P, Blažek M. LABORATORY ASSESSMENT OF HAEMOSTASIS IN CARDIOLOGICAL INTERVENTIONS. Interv Akut Kardiol. 2005;4(2):90-92.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andersson LO, Borrowcliffe TW, Holmer E, et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb. Res. 1979; 115: 531-541. Go to original source... Go to PubMed...
    2. Awtry HA, Loscalzo J. Aspirin. Circulation, 2000; 101: 1206-1218. Go to original source... Go to PubMed...
    3. Badimon L, Badimon JJ. Interaction of platelet activation and coagulation. In: Fuster V, Topol EJ, eds. Atherosklerosis and coronary artery disease. Lippincott-Raven Publishers, Philadelphia 1996: 639-656.
    4. Bultas J, Karetová D. Léčba trombotických stavů - kde jsme a kam se ubíráme. Remedia 2004; 14, č.2: 182-200.
    5. Dalen JE. An apple a day or an aspirin a day. Arch. Intern. Med. 1991; 151: 1066-1069. Go to original source... Go to PubMed...
    6. Hirmerová J, Filipovský J. Klinický význam aspirinové rezistence. Vnitř. Lék., 2004; 50, č. 6: 462-469.
    7. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low molecular weight heparin. Chest 2001; 119: 64S-94S. Go to original source... Go to PubMed...
    8. Marder VJ, Sherry S. Thrombolytic therapy: Current status (2). New Engl. Med. 1988; 318: 1512-1520. Go to original source... Go to PubMed...
    9. Mark DB, et al. Effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptakinase for acute myacardial infarction. New Engl. J. Med. 1995; 332: 1418-1424. Go to original source... Go to PubMed...
    10. McKee SA, Sane DC, Dellargyris EN. Aspirin resistance in cardiovascular diseases: A review of prevalence, mechanisms and clinical significance. Thromb. Haemost. 2002; 88: 711-715. Go to original source... Go to PubMed...
    11. McLean J. The thromboplastic action of cephalin. Am. J. Physiol. 1916; 41: 250-257. Go to original source...
    12. Novak J, Bucha S. Ecarin test. Semin. Thrombos. Haemostas. 1996; 22: 197-202. Go to original source...
    13. Patrono C, Coller B, Dalen JE, et al. Platelet - Active Drugs. The relationship among dose, effectiveness and side effects. Chest 2001; 119: 39-63. Go to original source... Go to PubMed...
    14. Pecka M, Gregor J, Urbankova J, Pudil J, Maly J. Use of propyl gallate in monitoring of antiaggregation therapy with ASA in patients with cardiovascular syndrome in. Reports from the 17 th International Congress on Thrombosis 2002, ed. Cocheri S, Gensini G, Palareti G, Prisce D. Monduzzi Ed. s. 15-18.
    15. Samama MM, Elalamy I. Aspirine et hémostase. Rev. Méd. Interne 2000; 21, Suppl. 1: 27-34. Go to original source... Go to PubMed...
    16. Vane JR, Bakhle YS, Botting RM. Cyklooxygenases 1 a 2. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 97-120. Go to original source... Go to PubMed...
    17. Vojáček J. Inhibitory destičkových glykoproteinových receptorů typu IIb/IIIa. Remedia 2003; 13, č. 2: 84-92.
    18. Vojáček J, Malý M, Hraboš V, et al. Hladina tkáňového faktoru, inhibitoru tkáňového faktoru a solubilního P-selektinu u nemocných s akutním koronárním syndromem. Cor. Vasa 2002; 44: 148-151.
    19. Widimský J, Malý J. Akutní plicní embolie a žilní trombóza, Nakl. Triton 2002: 304 s.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.